umu.sePublikasjoner
Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Rituximab in multiple sclerosis: a retrospective observational study on safety and efficacy
Umeå universitet, Medicinska fakulteten, Institutionen för farmakologi och klinisk neurovetenskap, Klinisk neurovetenskap.
Umeå universitet, Medicinska fakulteten, Institutionen för farmakologi och klinisk neurovetenskap, Klinisk neurovetenskap. Department of Clinical Neuroscience, Danderyd Hospital, Karolinska Institutet, Stockholm.
Vise andre og tillknytning
2016 (engelsk)Inngår i: Neurology, ISSN 0028-3878, E-ISSN 1526-632X, Vol. 87, nr 20, s. 2074-2081Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Objective: To investigate the safety and efficacy of rituximab in multiple sclerosis (MS). Methods: In this retrospective uncontrolled observational multicenter study, off-label rituximab-treated patients with MS were identified through the Swedish MS register. Outcome data were collected from the MS register and medical charts. Adverse events (AEs) grades 2-5 according to the Common Terminology Criteria for Adverse Events were recorded. Results: A total of 822 rituximab-treated patients with MS were identified: 557 relapsing-remitting MS (RRMS), 198 secondary progressive MS (SPMS), and 67 primary progressive MS (PPMS). At baseline, 26.2% had contrast-enhancing lesions (CELs). Patients were treated with 500 or 1,000 mg rituximab IV every 6-12 months, during a mean 21.8 (SD 14.3) months. During treatment, the annualized relapse rates were 0.044 (RRMS), 0.038 (SPMS), and 0.015 (PPMS), and 4.6% of patients displayed CELs. Median Expanded Disability Status Scale remained unchanged in RRMS (p = 0.42) and increased by 0.5 and 1.0 in SPMS and PPMS, respectively (p = 0.10 and 0.25). Infusion-related AEs occurred during 7.8% of infusions and most were mild. A total of 89 AEs grades >= 2 (of which 76 infections) were recorded in 72 patients. No case of progressive multifocal leukoencephalopathy was detected. Conclusions: This is the largest cohort of patients with MS treated with rituximab reported so far. The safety, clinical, and MRI findings in this heterogeneous real-world cohort treated with different doses of rituximab were similar to those reported in previous randomized controlled trials on B-cell depletion therapy in MS. Classification of evidence: This study provides Class IV evidence that for patients with MS, rituximab is safe and effective.

sted, utgiver, år, opplag, sider
2016. Vol. 87, nr 20, s. 2074-2081
HSV kategori
Identifikatorer
URN: urn:nbn:se:umu:diva-132168DOI: 10.1212/WNL.0000000000003331ISI: 000392236100007PubMedID: 27760868OAI: oai:DiVA.org:umu-132168DiVA, id: diva2:1078690
Tilgjengelig fra: 2017-03-06 Laget: 2017-03-06 Sist oppdatert: 2018-06-09bibliografisk kontrollert

Open Access i DiVA

fulltext(646 kB)1066 nedlastinger
Filinformasjon
Fil FULLTEXT01.pdfFilstørrelse 646 kBChecksum SHA-512
757321e77a2c77aaf3fceb1333999e2a365d73f72d372b8af315da07416d507320aa0e832d1b8efa10f4d4737d2ea3f8c995329b5e9a1e20e38dca5b39ae1677
Type fulltextMimetype application/pdf

Andre lenker

Forlagets fulltekstPubMed

Personposter BETA

Salzer, JonatanVågberg, MattiasSundström, PeterSvenningsson, Anders

Søk i DiVA

Av forfatter/redaktør
Salzer, JonatanVågberg, MattiasSundström, PeterSvenningsson, Anders
Av organisasjonen
I samme tidsskrift
Neurology

Søk utenfor DiVA

GoogleGoogle Scholar
Totalt: 1066 nedlastinger
Antall nedlastinger er summen av alle nedlastinger av alle fulltekster. Det kan for eksempel være tidligere versjoner som er ikke lenger tilgjengelige

doi
pubmed
urn-nbn

Altmetric

doi
pubmed
urn-nbn
Totalt: 393 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf